After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22

Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather

Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much

Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of

With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.1%, Nanexa

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount

Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum. NEX-20 is set to provide a more detailed

After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with

The combination of an exclusive evaluation agreement and directed share issue to Novo Nordisk, global leader in diabetes treatment, provides

Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2

Nanexa’s next proprietary development project, NEX-22, is a long-acting formulation of liraglutide for treatment of type 2 diabetes (T2D). Addressing

Johan Widmark | 2022-06-13 08:00  READ FULL REPORT HERE IN PDF New facility up and running While the inauguration of